



Jo Pharma Limited
"Care that everyone can share"
CIN: U23109DL2015PLC288456

JO PHARMA LIMITED

(Formerly known as Jo Pharma Private Limited.)

CIN: U23109DL2015PLC288456

Director's Report 2024-25

DIRECTOR'S REPORT

To
The Members,

Your directors have pleasure in presenting the 10th Annual Report ("Report") of Jo Pharma Limited along with the Audited Statement of Accounts for the financial year ended **March 31, 2025**.

1. FINANCIAL SUMMARY

The Company's financial performance, for the year ended March 31, 2025:

(Amount in Lakhs.)

Particulars	Year ended 31 st March 2025 (In Lakhs)	Year ended 31 st March 2024 (In Lakhs)
Turnover	3923.54	4,362.85
Profit Before Tax	274.70	310.95
Less: Current Tax	49.54	59.50
Deferred Tax	-19.58	-24.18
Income Tax earlier years	0.00	0.00
Profit For the Year	205.31	227.27

2. STATE OF AFFAIRS

1. The Company is engaged in the business of manufacture, import, export, wholesale, retail of Pharmaceutical Products, medical devices and Hygiene Products.
2. During the financial year under review, the Company received approval dated **04th December 2024** from the **Ministry of Corporate Affairs (MCA)** for the conversion of its status from a **Private Limited Company** to a **Public Limited Company**, following the requisite approval of the Members at the **Extra-Ordinary General Meeting (EGM)** held on **09th September 2024**.
3. Apart from the above-mentioned change in the Company's legal status, there have been **no other material changes** in the business affairs of the Company during the financial year ended **31st March 2025**.

3. COMPANY OVERVIEW AND PERFORMANCE

Your Company has earned a total income of Rs. **205.31** (in Lakhs) for the year under review as against Rs. **227.27** (in Lakhs) during the previous year and has reported a Profit before tax of Rs. **274.70** (in Lakhs) as against the profit before tax of Rs. **310.95** (in lakhs) in the previous year.

After providing Rs. **49.54** (in Lakhs) [previous year Rs. **59.50** (in Lakhs)] towards tax, your company has posted a net profit of Rs. **205.31** (in Lakh), as against the net profit of Rs. **227.27** (in Lakhs) in the previous year.

4. DIVIDEND

Your directors have assessed the ongoing financial condition of company or keeping the growth prospect of the business, board has decided not to recommend any dividend for period under review and internal accrual will be part of retained earnings.

5. TRANSFER TO GENERAL RESERVES

During the Financial Year under review, Profits of Rs. **205.31** /- (In Lakhs) has been transferred to General Reserve.

6. CHANGE IN DIRECTORSHIP

During the year under review, Mr. Suresh Baid was appointed as an Additional Director of the Company with effect from 22nd August, 2024, pursuant to the provisions of Section 161 of the Companies Act, 2013.

He held office as an Additional Director up to the date of the ensuing Annual General Meeting. The Members of the Company, at the Annual General Meeting held on 30th September, 2024, approved the regularization of Mr. Suresh Baid as a Director of the Company.

7. BOARD'S COMMENT ON THE AUDITORS' REPORT

The observations of the Statutory Auditors, when read together with the relevant notes to the accounts and accounting policies are self-explanatory and do not call for any further explanation or comments from the Board under Section 134(3) of the Companies Act, 2013.

8. MEETINGS OF BOARD OF DIRECTORS

During the Financial Year under review, the board of directors of your company met 9 times to transact the business of company in accordance with the provision of the Act and rules made thereunder and the dates on which they met during the year under review are as under:

S. No.	Date of Board Meeting	Attendance		
		Rakshit Jindal	Ankit Jindal	Suresh Baid
1.	08/04/2024	P	P	-
2.	10/06/2024	P	P	-
3.	12/08/2024	P	P	-
4.	22/08/2024	P	P	P

5.	28/08/2024	P	P	P
6.	02/09/2024	P	P	P
7.	14/10/2024	P	P	AB
8.	13/01/2025	P	P	AB
9.	07/02/2025	P	P	AB

9. WEB LINK OF ANNUAL RETURN, IF ANY.

Pursuant to sub-section 3(a) of Section 134 and sub-section (3) of Section 92 of the Act, read with Rule 11 and 12 of the Companies (Management and Administration) Rules, 2014, copy of Annual Return as at March 31, 2025 in Form No. **MGT-7** be hosted on the website of the Company and can be viewed at below mentioned link: <https://jopharma.com/annual-report/>

10. BUSINESS RISK MANAGEMENT

The Company does not have any Risk Management Policy, as the elements of risk threatening the Company's existence, is very minimal.

11. SUBSIDIARY/JOINT VENTURES/ASSOCIATE COMPANIES

The Company has no Subsidiary/Joint Ventures/Associate Companies as on 31st March, 2025. As such the company is not required to consolidate its account with any other company.

12. STATUTORY AUDITORS

ABNG & Company, Chartered Accountants (**FRN: 027223N**), were appointed as the Statutory Auditors of the Company by the Shareholders at the 8th Annual General Meeting to hold office till the conclusion of Annual General Meeting of the Company to be held in the year 2028."

The Notes on Accounts read with the Auditors' Reports are self-explanatory and therefore, do not call for any further comments or explanations. The Statutory Auditor's Report does not contain any qualification, reservation or adverse remark.

13. DETAILS IN RESPECT OF FRAUD REPORTED BY AUDITOR:

There were no qualifications or adverse remarks or reservations or disclaimers made by the Auditors in their Report on the financial statement of the company as on March 31, 2025.

Further, during the year under review, the Auditors have not reported any fraud under Section 143(12) of the Companies Act, 2013 and rules made there under.

14. MATERIAL CHANGES AND COMMITMENTS:

Except for the change in the legal status of the Company from a Private Limited Company to a Public Limited Company, as approved by the Ministry of Corporate Affairs (MCA) on **04th December, 2024**, there have been no other material changes or commitments which have occurred between the end of the financial year i.e., 31st March, 2025, and the date of this report that could affect the financial position or operations of the Company.

15. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS, COURTS AND TRIBUNALS

During the year under review, there were no significant and material order has been passed by the regulators, courts, tribunals impacting the going concern status and Company's operations in future.

16. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION & FOREIGN EXCHANGE DEALINGS

A. Conservation of energy

During the Financial Year under review, the Company has taken all possible steps for energy conservation.

B. Technology absorption

During the Financial Year under review, the Company has taken all initiatives for technology absorption.

C. Foreign Exchange Dealings

All Foreign exchange incomings or foreign exchange outgoings during the Financial Year under review forms part of the Balance Sheet.

17. DIRECTOR'S RESPONSIBILITY STATEMENT:

Pursuant to Section 134(5) of the Companies Act, 2013 the Board of Directors of the Company confirms that-

- a)** In the preparation of the annual accounts for the year ended March 31, 2025, the applicable accounting standards read with requirements set out under Schedule III to the Act, have been followed and there are no material departures from the same.
- b)** The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at March 31,2025 and of the profit of the Company for the year ended on that date.
- c)** The Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.
- d)** The Directors have prepared the annual accounts on a 'going concern' basis.
- e)** The Company being unlisted, sub clause (e) of section 134(3) of the Companies Act, 2013 pertaining to laying down internal financial controls is not applicable to the Company.

18. COMPLIANCE WITH SECRETARIAL STANDARD:

Further, during the period ending 31st March, 2025, the Company has complied with all the applicable Secretarial Standards Issued by the Institute of Company Secretaries of India and notified by Ministry of Corporate Affairs.

19. DEPOSITS

Your Company neither invited nor accepted any Deposit during the Financial Year ended March 31, 2025 under review.

20. INTER CORPORATE LOANS AND INVESTMENTS- SECTION 186

During the year under review, your Company has not extended any loan or guarantee, or provided any security or made any investment, pursuant to the provisions of Section 186 of the Companies Act, 2013 read with Rules made thereunder.

21. RELATED PARTY TRANSACTION- SECTION 188

All related party transactions that were entered into during the financial year ended 31st March, 2025 were on an arm's length basis and were in the ordinary course of business. Therefore, the provisions of Section 188 of the Companies Act, 2013 were not attracted. Further, there are no materially significant related party transactions during the year under review made by the Company with Promoters, Directors, or other designated persons which may have a potential conflict with the interest of the Company at large.

Thus, disclosure in Form AOC-2 is not required. However, the disclosure of transactions with related party for the year, as per Accounting Standard -18 Related Party Disclosures is given in Note no 28 to the Balance Sheet as on 31st March, 2025.

22. CONSTITUTION OF SEXUAL HARASSMENT COMMITTEE AT WORKPLACE

Prevention of Sexual Harassment of Employees at workplace and providing a safe and harassment free atmosphere is a matter of great importance for the Management. Right to protection from Sexual Harassment and right to work with dignity are recognised as universal Human Rights and the management endorses the same.

Your Company has zero tolerance for sexual harassment at workplace and in pursuance thereto had adopted a **Policy on Prevention, Prohibition and Redressal of Sexual Harassment at workplace** in line with the provisions of the **Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013** and the Rules made thereunder (herein after referred to as 'Act') for Prevention and Redressal of complaints of **Sexual Harassment at workplace**.

In compliance to the provisions of the Act, your Company has constituted Internal Complaint Committee (hereinafter referred as "ICC") covering all the employees working in various Offices of the Company.

During the reporting period, the ICC did not receive any complaints of sexual harassment.

The details of sexual harassment complaints for the reporting year are as follows:

Sexual Harassment Complaints	Number of Complaints
complaints received during the year	NIL
complaints disposed of during the year	NIL
cases pending for a period exceeding ninety days	NIL

23. COMPLIANCE WITH THE MATERNITY BENEFIT ACT, 1961

The Company reaffirms its commitment to promoting a supportive and inclusive workplace for all employees. In line with the applicable statutory requirements, the Company has ensured full compliance with the provisions of the Maternity Benefit Act, 1961, including the amendments thereto.

All eligible women employees are extended the benefits under the Act, including paid maternity leave, nursing breaks, and protection against dismissal during maternity leave. The Company remains committed to providing a safe, equitable, and enabling work environment for women, especially during and after maternity.

24. CORPORATE SOCIAL RESPONSIBILITY

During the Financial Year 2024-25, the Company was neither required to constitute a Corporate Social Responsibility (CSR) Committee nor spend any amount towards corporate social responsibility as per Section 135 of the Companies Act, 2013 and Rules made thereunder

25. MAINTENANCE OF COST RECORDS

During the period under review, maintenance of cost records as specified under Section 148(1) of the Companies Act, 2013 read with rules made thereunder is not applicable on the Company.

Accordingly, the Company was not required to make any such accounts and records during the year under review.

26. ACKNOWLEDGMENT

The Directors acknowledge with appreciation, the co-operation and assistance received from the Government, Banks, Authorities and other Business Constituents and arcade during the year.

Jo Pharma Limited
CIN: U23109DL2015PLC288456

Director's Report 2024-25

The Directors wish to place on record their appreciation of the contribution made by employees, customers and suppliers for their continuous support given by them to the Company at all levels during the period under report.

Your Board of Directors also takes this opportunity to convey their gratitude and sincere thanks for the co-operation & assistance received from the shareholders. The Board acknowledges your confidence and continued support and looks forward for the same in future as well.

Date: 12.09.2025
Place: New Delhi



For Jo Pharma Limited

For JO PHARMA LIMITED

A handwritten signature in blue ink, appearing to read 'Rakshit Jindal', written over the typed name and title.

Director

Rakshit Jindal
(Director)
DIN: 01820688
B-21, First Floor, Vasant Marg, Vasant Vihar-1, delhi - 110057

For JO PHARMA LIMITED

A handwritten signature in blue ink, appearing to read 'Ankit Jindal', written over the typed name and title.

Director

Ankit Jindal
(Director)
DIN: 02051735
B-21, First Floor, Vasant Marg, Vasant Vihar-1, delhi - 110057